Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone to Treat Fragile X Syndrome

RADNOR, Pa., Jan. 03, 2017 -- (Healthcare Sales & Marketing Network) -- Marinus Pharmaceuticals, Inc. (MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announ... Biopharmaceuticals, Neurology, FDA Marinus Pharmaceuticals, ganaxolone, Fragile X Syndrome
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news